<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39287394</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1935-5548</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Diabetes care</Title><ISOAbbreviation>Diabetes Care</ISOAbbreviation></Journal><ArticleTitle>Prevalent Metformin Use in Adults With Diabetes and the Incidence of Long COVID: An EHR-Based Cohort Study From the RECOVER Program.</ArticleTitle><Pagination><StartPage>1930</StartPage><EndPage>1940</EndPage><MedlinePgn>1930-1940</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Studies show metformin use before and during SARS-CoV-2 infection reduces severe COVID-19 and postacute sequelae of SARS-CoV-2 (PASC) in adults. Our objective was to describe the incidence of PASC and possible associations with prevalent metformin use in adults with type 2 diabetes mellitus (T2DM).</AbstractText><AbstractText Label="RESEARCH DESIGN AND METHODS" NlmCategory="METHODS">This is a retrospective cohort analysis using the National COVID Cohort Collaborative (N3C) and Patient-Centered Clinical Research Network (PCORnet) electronic health record (EHR) databases with an active comparator design that examined metformin-exposed individuals versus nonmetformin-exposed individuals who were taking other diabetes medications. T2DM was defined by HbA1c &#x2265;6.5 or T2DM EHR diagnosis code. The outcome was death or PASC within 6 months, defined by EHR code or computable phenotype.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the N3C, the hazard ratio (HR) for death or PASC with a U09.9 diagnosis code (PASC-U09.0) was 0.79 (95% CI 0.71-0.88; P &lt; 0.001), and for death or N3C computable phenotype PASC (PASC-N3C) was 0.85 (95% CI 0.78-0.92; P &lt; 0.001). In PCORnet, the HR for death or PASC-U09.9 was 0.87 (95% CI 0.66-1.14; P = 0.08), and for death or PCORnet computable phenotype PASC (PASC-PCORnet) was 1.04 (95% CI 0.97-1.11; P = 0.58). Incident PASC by diagnosis code was 1.6% metformin vs. 2.0% comparator in the N3C, and 2.1% metformin vs. 2.5% comparator in PCORnet. By computable phenotype, incidence was 4.8% metformin and 5.2% comparator in the N3C and 24.7% metformin vs. 26.1% comparator in PCORnet.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Prevalent metformin use is associated with a slightly lower incidence of death or PASC after SARS-CoV-2 infection. PASC incidence by computable phenotype is higher than by EHR code, especially in PCORnet. These data are consistent with other observational analyses showing prevalent metformin is associated with favorable outcomes after SARS-CoV-2 infection in adults with T2DM.</AbstractText><CopyrightInformation>&#xa9; 2024 by the American Diabetes Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Steven G</ForeName><Initials>SG</Initials><Identifier Source="ORCID">0000-0002-2983-6384</Identifier><AffiliationInfo><Affiliation>Institute for Health Informatics, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abedian</LastName><ForeName>Sajjad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Information Technologies and Services Department, Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St&#xfc;rmer</LastName><ForeName>Til</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huling</LastName><ForeName>Jared D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Division of Biostatistics and Health Data Science, University of Minnesota School of Public Health, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis V</LastName><ForeName>Colby</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buse</LastName><ForeName>John B</ForeName><Initials>JB</Initials><Identifier Source="ORCID">0000-0002-9723-3876</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brosnahan</LastName><ForeName>Shari B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Medicine, New York University Grossman School of Medicine, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mudumbi</LastName><ForeName>Praveen C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Population Health, New York University Grossman School of Medicine, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erlandson</LastName><ForeName>Kristine M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>University of Colorado, Anschutz Medical Campus, Aurora, CO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McComsey</LastName><ForeName>Grace A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Case Western Reserve University, Cleveland, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wiggen</LastName><ForeName>Talia D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Institute for Health Informatics, University of Minnesota, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and the Department of Internal Medicine, Stony Brook University, Stony Brook, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murphy</LastName><ForeName>Shawn</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mass General Brigham, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Clifford</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>MaineHealth Institute for Research, Scarborough, ME.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaushal</LastName><ForeName>Rainu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>Mark G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bramante</LastName><ForeName>Carolyn</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>RECOVER PCORnet EHR Cohort and the N3C Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30DK124723</GrantID><Agency>NC Diabetes Research Center</Agency><Country/></Grant><Grant><GrantID>K23 DK124654</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2HL16184701</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AG056479</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 TR004406</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 HL161847</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1 TR004528</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK124723</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG056479</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DK124654</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UM1TR004406</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 TR002306</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Diabetes Care</MedlineTA><NlmUniqueID>7805975</NlmUniqueID><ISSNLinking>0149-5992</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Duality of Interest.</b> T.S. receives salary support from the Center for Pharmacoepidemiology (current members: GlaxoSmithKline, UCB BioSciences, Takeda, AbbVie, Boehringer Ingelheim, Astellas, and Sarepta) in the Department of Epidemiology, and owns stock in Novartis, Roche, and Novo Nordisk. J.B.B. has received grant support from Bayer, Boehringer-Ingelheim, Carmot, Corcept, Dexcom, Eli Lilly, Insulet, MannKind, Novo Nordisk, and vTv Therapeutics; consulting contracts from Alkahest, Altimmune, Anji, Aqua Medical Inc, AstraZeneca, Boehringer-Ingelheim, CeQur, Corcept Therapeutics, Dasman Diabetes Center (Kuwait), Eli Lilly, embecta, Fortress Biotech, GentiBio, Glyscend, Insulet, Mediflix, Medscape, Mellitus Health, Metsera, Moderna, Novo Nordisk, Pendulum Therapeutics, Praetego, ReachMD, Stability Health, Tandem, Terns Inc, and Vertex; expert witness engagement by Medtronic MiniMed; and stock options from Glyscend, Mellitus Health, Pendulum Therapeutics, Praetego, and Stability Health. No other potential conflicts of interest relevant to this article were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>17</Day><Hour>21</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>17</Day><Hour>9</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39287394</ArticleId><ArticleId IdType="pmc">PMC11502533</ArticleId><ArticleId IdType="doi">10.2337/DCa24-0032</ArticleId><ArticleId IdType="pii">157171</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, et al. .; RECOVER Consortium . Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA 2023;329:1934&#x2013;1946</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Agarwal A, Alwan N, Luyckx VA. Long COVID: long-term health outcomes and implications for policy and research. Nat Rev Nephrol 2023;19:1&#x2013;2</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9628426</ArticleId><ArticleId IdType="pubmed">36319780</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, et al. .; the Northwell COVID-19 Research Consortium . Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323:2052&#x2013;2059</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Palaiodimos L, Kokkinidis DG, Li W, et al. . Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism 2020;108:154262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228874</ArticleId><ArticleId IdType="pubmed">32422233</ArticleId></ArticleIdList></Reference><Reference><Citation>Harding JL, Oviedo SA, Ali MK, et al. . The bidirectional association between diabetes and long-COVID-19 - a systematic review. Diabetes Res Clin Pract 2023;195:110202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9727969</ArticleId><ArticleId IdType="pubmed">36496030</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. .; ISB-Swedish COVID-19 Biobanking Unit . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022;185:881&#x2013;895.e20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Huling JD, Tignanelli CJ, et al. .; COVID-OUT Trial Team . Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19. N Engl J Med 2022;387:599&#x2013;610</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9945922</ArticleId><ArticleId IdType="pubmed">36070710</ArticleId></ArticleIdList></Reference><Reference><Citation>Ventura-L&#xf3;pez C, Cervantes-Luevano K, Aguirre-S&#xe1;nchez JS, et al. . Treatment with metformin glycinate reduces SARS-CoV-2 viral load: an in&#xa0;vitro model and randomized, double-blind, phase IIb clinical trial. Biomed Pharmacother 2022;152:113223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9159967</ArticleId><ArticleId IdType="pubmed">35709650</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan LE, Casiraghi E, Laraway B, et al. .; N3C consortium . Metformin is associated with reduced COVID-19 severity in patients with prediabetes. Diabetes Res Clin Pract 2022;194:110157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9663381</ArticleId><ArticleId IdType="pubmed">36400170</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Johnson SG, Garcia V, et al. .; N3C core authors . Diabetes medications and associations with Covid-19 outcomes in the N3C database: a national retrospective cohort study. PLoS One 2022;17:e0271574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671347</ArticleId><ArticleId IdType="pubmed">36395143</ArticleId></ArticleIdList></Reference><Reference><Citation>Pernicova I, Korbonits M. Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014;10:143&#x2013;156</Citation><ArticleIdList><ArticleId IdType="pubmed">24393785</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun T, Liu J, Xie C, Yang J, Zhao L, Yang J. Metformin attenuates diabetic renal injury via the AMPK-autophagy axis. Exp Ther Med 2021;21:578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8027752</ArticleId><ArticleId IdType="pubmed">33850550</ArticleId></ArticleIdList></Reference><Reference><Citation>Karam BS, Morris RS, Bramante CT, et al. . mTOR inhibition in COVID-19: a commentary and review of efficacy in RNA viruses. J Med Virol 2021;93:1843&#x2013;1846</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8159020</ArticleId><ArticleId IdType="pubmed">33314219</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Buse JB, Liebovitz DM, et al. .; COVID-OUT Study Team . Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial. Lancet Infect Dis 2023;23:1119&#x2013;1129</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Lv X, Lin S, Arshad M, Dai M. The association between antidiabetic agents and clinical outcomes of COVID-19 patients with diabetes: a Bayesian network meta-analysis. Front Endocrinol (Lausanne) 2022;13:895458.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9186017</ArticleId><ArticleId IdType="pubmed">35692410</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel MA, Chute CG, Bennett TD, et al. .; N3C Consortium . The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. J Am Med Inform Assoc 2021;28:427&#x2013;443</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence RL, Curtis LH, Califf RM, Platt R, Selby JV, Brown JS. Launching PCORnet, a national patient-centered clinical research network. J Am Med Inform Assoc 2014;21:578&#x2013;582</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang C, Zhang Y, Xu J, et al. . Data-driven analysis to understand long COVID using electronic health records from the RECOVER initiative. Nat Commun 2023;14:1948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10080528</ArticleId><ArticleId IdType="pubmed">37029117</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Notifiable Diseases Surveillance System . Coronavirus disease 2019 (COVID-19) 2021 case definition. 2021. https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/. Accessed 24 Feb 2024</Citation></Reference><Reference><Citation>Pfaff ER, Girvin AT, Bennett TD, et al. .; N3C Consortium . Identifying who has long COVID in the USA: a machine learning approach using N3C data. Lancet Digit Health 2022;4:e532&#x2013;e541</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110014</ArticleId><ArticleId IdType="pubmed">35589549</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zang C, Xu Z, et al. . Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. Nat Med 2023;29:226&#x2013;235</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9873564</ArticleId><ArticleId IdType="pubmed">36456834</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock SJ, Stone GW. The primary outcome fails - what next? N Engl J Med 2016;375:861&#x2013;870</Citation><ArticleIdList><ArticleId IdType="pubmed">27579636</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou GN, Berry K, Rajeevan N, et al. . Effectiveness of nirmatrelvir-ritonavir against the development of post-COVID-19 conditions among U.S. veterans: a target trial emulation. Ann Intern Med 2023;176:1486&#x2013;1497</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620954</ArticleId><ArticleId IdType="pubmed">37903369</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund JL, Richardson DB, St&#xfc;rmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep 2015;2:221&#x2013;228</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4778958</ArticleId><ArticleId IdType="pubmed">26954351</ArticleId></ArticleIdList></Reference><Reference><Citation>58th EASD Annual Meeting of the European Association for the Study of Diabetes: Stockholm, Sweden, 19 - 23 September 2022. Diabetologia 2022;65:1&#x2013;469</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9362525</ArticleId><ArticleId IdType="pubmed">35920845</ArticleId></ArticleIdList></Reference><Reference><Citation>Berndt J, Ooi SL, Pak SC. What is the mechanism driving the reduction of cardiovascular events from glucagon-like peptide-1 receptor agonists?-A mini review. Molecules 2021;26 10.3390/molecules26164822</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules26164822</ArticleId><ArticleId IdType="pmc">PMC8400553</ArticleId><ArticleId IdType="pubmed">34443410</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehdi SF, Pusapati S, Anwar MS, et al. . Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol 2023;14:1148209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10230051</ArticleId><ArticleId IdType="pubmed">37266425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahkoska AR, Abrahamsen TJ, Alexander GC, et al. .; N3C Consortium . Association between glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use and COVID-19 outcomes. Diabetes Care 2021;44:1564&#x2013;1572</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8323175</ArticleId><ArticleId IdType="pubmed">34135013</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P, Sourij H, Aberer F, Rilstone S, Schierbauer J, Moser O. SGLT2 inhibitors in long COVID syndrome: is there a potential role? JCDD 2023;10:478 10.3390/jcdd10120478</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd10120478</ArticleId><ArticleId IdType="pmc">PMC10744331</ArticleId><ArticleId IdType="pubmed">38132646</ArticleId></ArticleIdList></Reference><Reference><Citation>Crouse AB, Grimes T, Li P, Might M, Ovalle F, Shalev A. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. Front Endocrinol (Lausanne) 2020;11:600439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7838490</ArticleId><ArticleId IdType="pubmed">33519709</ArticleId></ArticleIdList></Reference><Reference><Citation>Castle BT, Dock C, Hemmat M, et al. . (2020) Biophysical modeling of the SARS-CoV-2 viral cycle reveals ideal antiviral targets. bioRxiv 2020.05.22.111237.</Citation></Reference><Reference><Citation>Gordon DE, Jang GM, Bouhaddou M, et al. . A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020;583:459&#x2013;468</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullen PJ, Garcia G, Purkayastha A, et al. . SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition. Nat Commun 2021;12:1876.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7994801</ArticleId><ArticleId IdType="pubmed">33767183</ArticleId></ArticleIdList></Reference><Reference><Citation>Howell JJ, Hellberg K, Turner M, et al. . Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab 2017;25:463&#x2013;471</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5299044</ArticleId><ArticleId IdType="pubmed">28089566</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Beckman KB, Mehta T, et al. . Favorable effects of metformin on SARS-CoV-2 viral load in a phase 3 randomized placebo controlled clinical trial. Clin Infect Dis In press.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11327787</ArticleId><ArticleId IdType="pubmed">38690892</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingraham NE, Lotfi-Emran S, Thielen BK, et al. . Immunomodulation in COVID-19. Lancet Respir Med 2020;8:544&#x2013;546</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7198187</ArticleId><ArticleId IdType="pubmed">32380023</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang W, Zhang J, Hong L, et al. . Metformin ameliorates stress-induced depression-like behaviors via enhancing the expression of BDNF by activating AMPK/CREB-mediated histone acetylation. J Affect Disord 2020;260:302&#x2013;313</Citation><ArticleIdList><ArticleId IdType="pubmed">31521867</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>